「jp」の検索結果
239件:176~180件目を表示
-

定です。 ・最新の電子化された添付文書(以下、電子添文)及び医薬品安全対策情報(DSU)は、PMDAホ ームページ「医薬品に関する情報」からご確認ください。 (https://www.pmda.go.jp/safety/info-services/drugs/0001.html) ・弊社医薬関係者向けWebサイトからもご覧いただけます。 (https://www.senju.co.jp/medic...
https://www.senju.co.jp/system/files/news_file/2026-03/BRN_202603_Revised Info.pdf -

Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; h...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -

Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; h...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -

nju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headq...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509.pdf -

nju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headq...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509_0.pdf